drugset
drugset / Trial / NCT04524962

Study of Descartes-30 in Acute Respiratory Distress Syndrome

NCT04524962 ↗

Phase 1 Terminated 12 enrolled Cartesian Therapeutics National Heart, Lung, and Blood Institute (NHLBI) · collab
NaSingle-groupOpen-labelTreatment

Summary

Emergency study to test the safety of Descartes-30 cells in patients with moderate-to-severe acute respiratory distress syndrome (ARDS) AND COVID-19

Timeline

Start
2021-02-23
Primary completion
2022-09-09
Completion
2023-09-09

Outcome

Outcome not reported

Stopped (Enrollment): “Phase 1 enrollment completed. Further clinical development terminated”

Drugs

EvaluationDrugModalityDoseRoute
Subject Descartes 30 Unknown — —

Indications

COVID-19 acute respiratory distress syndrome